You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Melanoma

Showing 26 - 50 of 5,258
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial (ABP 206, FDA-licensed Nivolumab, EU-authorized Nivolumab)

Not yet recruiting
  • Melanoma
  • ABP 206
  • +2 more
  • (no location specified)
Jun 8, 2023

Acral Melanoma Trial (camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab)

Not yet recruiting
  • Acral Melanoma
  • (no location specified)
Mar 16, 2023

Blocking TNF to Potentiate ICI-dependent Immune Awakening in

Recruiting
  • Melanoma
  • +2 more
    • Toulouse, France
      Institut Claudius Regaud
    May 25, 2023

    Advanced Melanoma Trial in Basel (Combination of Tumor-infiltrating lymphocyte transfer with ANV419)

    Not yet recruiting
    • Advanced Melanoma
    • Combination of Tumor-infiltrating lymphocyte transfer with ANV419
    • Basel, Switzerland
      University Hospital Basel
    May 19, 2023

    Melanoma Stage III Trial in Shanghai (Toripalimab combined with Temozolomide)

    Not yet recruiting
    • Melanoma Stage III
    • Toripalimab combined with Temozolomide
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 23, 2023

    Melanoma (Skin) Trial (Sodium Chloride Granules, Water)

    Not yet recruiting
    • Melanoma (Skin)
    • Sodium Chloride Granules
    • Water
    • (no location specified)
    May 2, 2023

    Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma Trial in Leiden (Encorafenib + Binimetinib)

    Recruiting
    • Melanoma Stage III
    • In-Transit Metastasis of Cutaneous Melanoma
    • Encorafenib + Binimetinib
    • Leiden, Zuid-Holland, Netherlands
      Leiden University Medical Center
    Mar 2, 2023

    Healthcare Resource Utilization and Costs in Metastatic Melanoma

    Terminated
    • Metastatic Melanoma
      • East Hanover, New Jersey
        Novartis Investigational Site
      Apr 27, 2023

      Baseline Metastases on Clinical Outcomes Among BRAF Positive

      Completed
      • BRAF Positive Metastatic Melanoma
        • East Hanover, New Jersey
          Novartis
        Aug 2, 2023

        Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 Trial in Jacksonville (drug,

        Active, not recruiting
        • Metastatic Melanoma
        • +3 more
        • Jacksonville, Florida
          Mayo Clinic in Florida
        Jan 3, 2023

        Morphological, Genetic and Tumour Microenvironment

        Recruiting
        • Uveal Melanoma
        • cytogenetic analysis on tumour tissue
        • Digital Pathology
        • Rome, Italy
          Monica Maria Pagliara - Oncologia Oculare
        May 26, 2023

        Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma

        Recruiting
        • Clinical Stage I Cutaneous Melanoma AJCC v8
        • +13 more
        • Houston, Texas
          M D Anderson Cancer Center
        Dec 16, 2022

        Melanoma Trial in Scottsdale (Educational Intervention, Questionnaire Administration)

        Active, not recruiting
        • Melanoma
        • Educational Intervention
        • Questionnaire Administration
        • Scottsdale, Arizona
          Mayo Clinic in Arizona
        Jan 4, 2023

        Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV Trial in Iowa City, Rochester, Madison ([212Pb]VMT01)

        Not yet recruiting
        • Melanoma (Skin)
        • +5 more
        • Iowa City, Iowa
        • +2 more
        Dec 8, 2022

        Gut and Tumor Microbiome in Advanced ER-positive and

        Not yet recruiting
        • Breast Cancer
        • Melanoma
        • Observation
        • (no location specified)
        Nov 6, 2023

        Metastatic Uveal Melanoma Trial in Grand Rapids (IDE196, Crizotinib, Pembrolizumab)

        Recruiting
        • Metastatic Uveal Melanoma
        • Grand Rapids, Michigan
          The Cancer and Hematology Centers
        Aug 14, 2023

        Immunotherapy in Patients With Metastatic Melanoma

        Not yet recruiting
        • Metastatic Melanoma
        • data collection
        • (no location specified)
        Nov 28, 2022

        Tumor Infiltrating Lymphocytes, Safety, Melanoma Trial in Beijing (GC101 TIL)

        Recruiting
        • Tumor Infiltrating Lymphocytes
        • +4 more
        • GC101 TIL
        • Beijing, China
          Beijing Cancer Hospital
        Nov 7, 2023

        Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral) Trial in Ljubljana (Immune

        Recruiting
        • Metastatic Melanoma
        • +3 more
        • Immune checkpoint inhibitor
        • Ljubljana, Slovenia
          Institute of Oncology Ljubljana
        May 17, 2023

        Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)

        Recruiting
        • Melanoma
        • Metastatic Melanoma
        • Boston, Massachusetts
          Dana-Farber Cancer Institute
        Jan 12, 2023

        Generation ofArtificial Intelligence Algorithm Based on Analysis

        Not yet recruiting
        • Metastatic Melanoma
        • Photo
        • (no location specified)
        May 3, 2023

        Melanoma Trial in Philadelphia (Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab)

        Active, not recruiting
        • Melanoma
        • Mature dendritic cell (DC) vaccine
        • +2 more
        • Philadelphia, Pennsylvania
          University of Pennsylvania
        Feb 2, 2023

        Melanoma Trial (V940, Pembrolizumab, Placebo)

        Not yet recruiting
        • Melanoma
        • V940
        • +2 more
        • (no location specified)
        Jul 12, 2023

        Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial in Shanghai (Endostar,

        Recruiting
        • Clinical Stage III Cutaneous Melanoma AJCC v8
        • Clinical Stage IV Cutaneous Melanoma AJCC v8
        • Shanghai, China
          Fudan University Shanghai Cancer Center
        Jun 17, 2023

        Metastatic Melanoma, Unresectable Melanoma, Melanoma Trial (Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover

        Not yet recruiting
        • Metastatic Melanoma
        • +2 more
        • Lifileucel plus Pembrolizumab
        • Pembrolizumab with Optional Crossover Period
        • (no location specified)
        Feb 13, 2023